medigraphic.com
ISSN 1561-3054 (Electronic)

2020, Number 3

<< Back Next >>

Rev Cubana Med Trop 2020; 72 (3)

COVID-19 morbidity: analysis of epidemiological, clinical and diagnostic aspects

Bandera JDC, Morandeira PH, Valdés GLE, Rodríguez VA, Sagaró CN, Palú OA, Romero ML

Language: Spanish
References: 17
Page: 1-14
PDF size: 356.79 Kb.


ABSTRACT

Introduction: COVID-19, a disease caused by the virus named SARS-CoV-2, was declared pandemic by the WHO in March 2020. Until 9 June Cuba had reported 2 211 cases and 83 deaths. Forty-nine of these cases were from Santiago de Cuba, for a lethality of 6.12.
Objective: Characterize COVID-19 morbidity in Santiago de Cuba based on the analysis of selected epidemiological, clinical and diagnostic aspects.
Method: A descriptive cross-sectional study was conducted of the 49 patients confirmed in the province. A review was performed of databases, statistics, and clinical and epidemiological records. Estimation was made of incidence rates, arithmetic mean and median, percentage difference between the rates, and Fischer's exact test. Statistical association was determined with the software EPIDAT, using a confidence level of 95% and a significance level of ≤ 0.05.
Results: The incidence rate was 4.7 per 1 000 inhabitants. The municipalities involved were Santiago, Contramaestre and Palma Soriano. The greatest risk lay in patients aged over 60 years, among whom coughing, fever and rhinitis were common symptoms. Of the patients studied, 26.53% were asymptomatic. The main associated comorbidities were hypertension and neurological and respiratory disorders. The results of the diagnostic procedures applied were positive RT-PCR, high LDH, C-reactive protein, hyperglycemia and diffuse inflammatory pulmonary infiltrate. A statistical association was found between the evolution period, 7 and more days from symptom onset to admission, and the degree of severity.
Conclusions: The highest risk of becoming ill and dying was found in the most advanced ages of life. The most common symptoms behaved in a manner similar to the one described in the bibliography consulted, and so did the laboratory results obtained. Delay in reporting to health institutions and associated comorbidities were risks for progression to severity and death.


REFERENCES

  1. Ministerio de Sanidad. Enfermedad por coronavirus, COVID-19. Actualización, [Internet]. 4 de Abril 2020 [acceso: 25/05/2020]. Disponible en: Disponible en: https://medicostenerife.es/wp-content/uploads/2020/04/ACTUALIZACI%C3%93N-6-ABRIL 20200404_ITCoronavirus-4-abril1.pdf

  2. Cuba. Ministerio de Salud Pública. Parte de Cierre del día 11 de mayo a las 12 de la noche. Sitio Oficial de Gobierno del Ministerio de Salud Pública en Cuba [Internet]. 12 de mayo de 2020 [acceso: 25/05/2020]. Disponible en: Disponible en: https://salud.msp.gob.cu/parte-de-cierre-del-dia-11-de-mayo-a-las-12-de-la-noche/

  3. Berlin AD, Gulick RM, Martinez FJ, M.D Severe Covid-19. The New England Journal of Medicine [Internet]. [acceso: 25/05/2020]. Disponible en: Disponible en: https://www.nejm.org/doi/full/10.1056/NEJMcp2009575

  4. Zangrillo A, Beretta L, Scandroglio AM. Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy Crit Care Resusc [Internet]. 2020 [acceso: 23/04/2020]. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32353223/

  5. Rodriguez-Morales AJ. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis [Internet]. March-April 2020 [acceso: 01/06/2020];34:101623. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102608/

  6. Kumar Singh A, Gupta R, Misra A. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes Metab Syndr[Internet]. 2020 [acceso: 02/06/2020];14(4):283-7. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144598/

  7. Guan W. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J [Internet]. May 2020 [acceso: 02/06/2020];55(5): 2000547. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098485/

  8. Yang J. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. International Journal of Infectious Diseases [Internet]. 2020 [acceso: 02/06/2020];94:91-5. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S1201971220301363

  9. Sociedad Europea de Endocrinología. COVID-19 y enfermedades endócrinas. [Internet]. 23 Abr 2020. [acceso: 02/06/2020]. Disponible en: Disponible en: https://www.intramed.net/contenidover.asp?contenidoid=96009

  10. Wu Y, Ching-Sung C, Yu-Jiun C.The outbreak of COVID-19: An overview. J Chin Med Assoc [Internet]. Mar 2020 [acceso 02/06/2020];83(3):217-20. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153464/

  11. Irabien-Ortiz A. Miocarditis fulminante por COVID-19. Rev Esp Cardiol. [Internet]. 2020 [acceso: 02/06/2020];73(6):503-15 Disponible en: Disponible en: https://www.revespcardiol.org/index.php?p=revista&tipo=pdf-simple&pii=S0300893220301743

  12. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol [Internet]. May 2020 [acceso: 02/06/2020];109(5):531-8. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32161990/

  13. Freund A. COVID-19: ¿Quiénes son los más afectados y por qué? [Internet]. 11 de marzo de 2020. [acceso: 25/05/2020]. Disponible en: Disponible en: https://www.dw.com/es/covid-19-qui%C3%A9nes-son-los-m%C3%A1s-afectados-y-por-qu%C3%A9/a-52728619

  14. Trilla A. Un mundo, una salud: la epidemia por el nuevo coronavirus COVID-19. Med Clin (Barc) [Internet]. 2020 [acceso: 27/05/2020];154(5):175177. Disponible en: Disponible en: https://www.elsevier.es/index.php?p=revista&pRevista=pdfsimple&pii=S002577532030141X

  15. Zhou F, Yu T, Du R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62.

  16. Wang D, Hu B, Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA [Internet]. 2020 [acceso: 27/05/2020];323:1061-9. Disponible en: Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2761044

  17. Centro Para el Control y la Prevención de Enfermedades. Preguntas frecuentes sobre el coronavirus (COVID-19) [Internet]. 2020 [acceso: 02/06/2020]. Disponible en: Disponible en: https://espanol.cdc.gov/coronavirus/2019-ncov/faq.html




2020     |     www.medigraphic.com